Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Mar 28, 2007

Pharmacopeia Pockets $1M Milestone Payment from Schering-Plough

  • Schering-Plough initiated a Phase I evaluation of an anti-inflammatory compound identified in collaboration with Pharmacopeia. The company will thus receive a $1-million milestone payment from Schering-Plough.

    "With four product candidates in clinical development, our collaboration with Schering-Plough is currently our most productive," comments Les Browne, Ph.D., president and CEO of Pharmacopeia.

    Schering-Plough is solely responsible for further development and commercialization of the candidate. Pharmacopeia is eligible to receive additional milestone payments based on clinical advancement and royalties on sales of any resulting therapeutic products incorporating compounds derived from the program.



Be sure to take the GEN Poll

Scientifically Studying Ecstasy

MDMA (commonly known as the empathogen “ecstasy”) is classified as a Schedule 1 drug, which is reserved for compounds with no accepted medical use and a high abuse potential. Two researchers from Stanford, however, call for a rigorous scientific exploration of MDMA's effects to identify precisely how the drug works, the data from which could be used to develop therapeutic compounds.

Do you agree that ecstasy should be studied for its potential therapeutic benefits?

More »